These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

931 related items for PubMed ID: 25592197

  • 1. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S, Study 05 Group.
    Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
    [Abstract] [Full Text] [Related]

  • 2. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
    Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E, Study 05 Group.
    Diabetes Obes Metab; 2015 Nov; 17(11):1075-84. PubMed ID: 26212528
    [Abstract] [Full Text] [Related]

  • 3. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA, Hardy E, Sugg J, Parikh S, Study 10 Group.
    Diabetes Care; 2014 Nov; 37(3):740-50. PubMed ID: 24144654
    [Abstract] [Full Text] [Related]

  • 4. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, Chen H, Hansen L, Iqbal N.
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [Abstract] [Full Text] [Related]

  • 5. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
    Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N.
    Diabetes Care; 2015 Mar; 38(3):376-83. PubMed ID: 25352655
    [Abstract] [Full Text] [Related]

  • 6. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
    Matthaei S, Catrinoiu D, Celiński A, Ekholm E, Cook W, Hirshberg B, Chen H, Iqbal N, Hansen L.
    Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
    [Abstract] [Full Text] [Related]

  • 7. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA.
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
    Müller-Wieland D, Kellerer M, Cypryk K, Skripova D, Rohwedder K, Johnsson E, Garcia-Sanchez R, Kurlyandskaya R, Sjöström CD, Jacob S, Seufert J, Dronamraju N, Csomós K.
    Diabetes Obes Metab; 2018 Nov; 20(11):2598-2607. PubMed ID: 29947099
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
    Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF.
    Diabet Med; 2015 Apr; 32(4):531-41. PubMed ID: 25381876
    [Abstract] [Full Text] [Related]

  • 10. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
    Rosenstock J, Perl S, Johnsson E, García-Sánchez R, Jacob S.
    Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
    Mathieu C, Herrera Marmolejo M, González González JG, Hansen L, Chen H, Johnsson E, Garcia-Sanchez R, Iqbal N.
    Diabetes Obes Metab; 2016 Nov; 18(11):1134-1137. PubMed ID: 27385192
    [Abstract] [Full Text] [Related]

  • 12. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
    Vilsbøll T, Ekholm E, Johnsson E, Dronamraju N, Jabbour S, Lind M.
    Diabetes Care; 2019 Aug; 42(8):1464-1472. PubMed ID: 31167892
    [Abstract] [Full Text] [Related]

  • 13. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA, Del Prato S, Durán-García S, Rohwedder K, Langkilde AM, Sugg J, Parikh SJ.
    Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
    [Abstract] [Full Text] [Related]

  • 14. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
    Haering HU, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Meinicke T, Woerle HJ, Broedl UC, EMPA-REG EXTEND™ METSU investigators.
    Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220
    [Abstract] [Full Text] [Related]

  • 15. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
    Matthaei S, Aggarwal N, Garcia-Hernandez P, Iqbal N, Chen H, Johnsson E, Chin A, Hansen L.
    Diabetes Obes Metab; 2016 Nov; 18(11):1128-1133. PubMed ID: 27403645
    [Abstract] [Full Text] [Related]

  • 16. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
    Jabbour SA, Frías JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C.
    Diabetes Care; 2018 Oct; 41(10):2136-2146. PubMed ID: 30082326
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study.
    Jeong IK, Choi KM, Han KA, Kim KA, Kim IJ, Han SJ, Lee WY, Yoo SJ.
    Diabetes Obes Metab; 2024 Nov; 26(11):5065-5077. PubMed ID: 39223856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.